Overview

Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype

Status:
Terminated
Trial end date:
2020-11-14
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-814 in PiZZ subjects.
Phase:
Phase 2
Details
Lead Sponsor:
Vertex Pharmaceuticals Incorporated